+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H1 2019

  • ID: 4750066
  • Drug Pipelines
  • 58 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Clexio Biosciences Ltd
  • Crossject SA
  • Eli Lilly and Co
  • Novartis AG
  • TrioxBio Inc
  • MORE
Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2019, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.

Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.

Report Highlights

This latest pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cluster Headache Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Clexio Biosciences Ltd
  • Crossject SA
  • Eli Lilly and Co
  • Novartis AG
  • TrioxBio Inc
  • MORE
Introduction

Report Coverage

Cluster Headache Syndrome (Cluster Headache) - Overview

Cluster Headache Syndrome (Cluster Headache) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cluster Headache Syndrome (Cluster Headache) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cluster Headache Syndrome (Cluster Headache) - Companies Involved in Therapeutics Development

Clexio Biosciences Ltd

Crossject SA

Eli Lilly and Co

Novartis AG

Teva Pharmaceutical Industries Ltd

TrioxBio Inc

Cluster Headache Syndrome (Cluster Headache) - Drug Profiles

CLE-500 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fremanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galcanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTR-108 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pasireotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

psilocybin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sumatriptan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zucapsaicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cluster Headache Syndrome (Cluster Headache) - Dormant Projects

Cluster Headache Syndrome (Cluster Headache) - Product Development Milestones

Featured News & Press Releases

Nov 14, 2018: Emgality receives Breakthrough Therapy Designation for prevention of Episodic Cluster Headache

Jun 15, 2018: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache

May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

Apr 17, 2018: Teva to Present New Data on Fremanezumab at 70th Annual Meeting of the American Academy of Neurology

Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Clexio Biosciences Ltd, H1 2019

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Crossject SA, H1 2019

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Eli Lilly and Co, H1 2019

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Novartis AG, H1 2019

Cluster Headache Syndrome (Cluster Headache) - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2019

Cluster Headache Syndrome (Cluster Headache) - Pipeline by TrioxBio Inc, H1 2019

Cluster Headache Syndrome (Cluster Headache) - Dormant Projects, H1 2019

List of Figures

Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H1 2019 7

Number of Products under Development by Companies, H1 2019 8

Number of Products by Targets, H1 2019 13

Number of Products by Stage and Targets, H1 2019 13

Number of Products by Mechanism of Actions, H1 2019 15

Number of Products by Stage and Mechanism of Actions, H1 2019 15

Number of Products by Routes of Administration, H1 2019 17

Number of Products by Stage and Routes of Administration, H1 2019 17

Number of Products by Molecule Types, H1 2019 19

Number of Products by Stage and Molecule Types, H1 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Clexio Biosciences Ltd
  • Crossject SA
  • Eli Lilly and Co
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • TrioxBio Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4750066
Adroll
adroll